CD105: tumor diagnosis, prognostic marker and future tumor therapeutic target.

Abstract

Cancer is one of the diseases with the highest morbidity and mortality rates worldwide, and its therapeutic options are inadequate. The endothelial glycoprotein, also known as CD105, is a type I transmembrane glycoprotein located on the surface of the cell membranes and it is one of the transforming growth factor-β (TGF-β) receptor complexes. It regulates the responses associated with binding to transforming growth factor β1 egg (Activin-A), bone morphogenetic protein 2 (BMP-2), and bone morphogenetic protein 7 (BMP-7). Additionally, it is involved in the regulation of angiogenesis. This glycoprotein is indispensable in the treatment of tumor angiogenesis, and it also plays a leading role in tumor angiogenesis therapy. Therefore, CD105 is considered to be a novel therapeutic target. In this study, we explored the significance of CD105 in the diagnosis, treatment and prognosis of various tumors, and provided evidence for the effect and mechanism of CD105 on tumors.

• Authors: Lan Li, Liping Zhong, Chao Tang, Lu Gan, Tong Mo, Jintong Na, Jian He, Yong Huang
• Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (Clin Transl Oncol) Vol. 24 Issue 8 Pg. 1447-1458 (Aug 2022) ISSN: 1699-3055 [Electronic] Italy
• PMID: 35165838 (Publication Type: Journal Article, Review)
• Copyright: © 2022. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO).

Chemical References

• Antigens, CD
• ENG protein, human
• Endoglin
• Receptors, Cell Surface
• Transforming Growth Factor beta

Topics

• Antigens, CD
• Endoglin
• Humans
• Neoplasms (diagnosis, therapy)
• Neovascularization, Pathologic (pathology)
• Prognosis
• Receptors, Cell Surface
• Transforming Growth Factor beta (metabolism)